Compare Sana Biotechnology Inc (SANA) vs Sony Group Corp (SONY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Sony Group Corp — how do they compare? Sana Biotechnology Inc trades at $2.79 (market cap $836.71M), while Sony Group Corp trades at $24.12 (market cap $136.87B). The key difference: Sony Group Corp is far larger — about 163.6× Sana Biotechnology Inc's market cap, and Sony Group Corp pays a 0.66% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sana Biotechnology Inc for 23 Days and Sony Group Corp for 96 Days on average.
| SANA | SONY | |
|---|---|---|
Market Cap | $836.71M | $136.87B |
Volume | 4,507,444 | 5,364,503 |
Sector | Health | Technology |
52-Week High | $5.92 | $30.26 |
52-Week Low | $2.68 | $19.32 |
Typical Hold Time | 23 Days | 96 Days |
Enterprise Value | $749.96M | $134.77B |
Dividend Yield | — | 0.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $2.79, up 2.57% today, but faces significant fundamental challenges with negative revenue, substantial losses, and bearish technical indicators. The company reported a net loss of $244.17 million in 2025 with no revenue, while technical analysis shows a bearish trend with moving averages and ADX indicators signaling selling pressure. Recent news highlights multiple investor conference presentations and ongoing legal scrutiny regarding fiduciary duties.
Despite strong analyst support (82% buy ratings), SANA's lack of revenue generation and negative profitability metrics present substantial investment risk. The company's cash flow remains negative, requiring continued financing. Near-term catalysts include upcoming Q3 earnings and clinical developments, but investors should weigh the high-risk profile against potential long-term biotechnology breakthroughs.
Sony trades at $23.95, up 1.83% with bullish technical signals from moving averages. The company shows strong operating cash flow of $2.32T in 2025 and has beaten earnings expectations in two of the last three quarters. Analyst consensus is strongly positive with 11 buy ratings and no sell recommendations. Recent news highlights Sony's content strength and AI-related legal actions against Anthropic.
While Sony demonstrates financial strength with improving cash flow and revenue growth, investors face risks from projected 2026 net losses and competitive pressures. The stock's current valuation appears reasonable with P/E of 20.34, but margin compression and content industry disruption require careful monitoring for sustained shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Sony Group Corp
Sony Group is a conglomerate with consumer electronics roots, which not only designs, develops, produces, and sells electronic equipment and devices, but also is engaged in content businesses, such as console and mobile games, music, and movies. Sony is a global top company of CMOS image sensors, game consoles, professional broadcasting cameras, and music publishing, and is one of the top players on digital cameras, wireless earphones, recorded music, movies, and so on. Sony's business portfolio is well diversified with six major business segments. The company fully consolidated Sony Financial in September 2020, which provides life and non-life insurance, banking, and other financial services.
Read more on SONY →
